SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Ruhling M.)
 

Search: WFRF:(Ruhling M.) >

Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis

Lancini, E. (author)
Haag, L. (author)
Bartl, F. (author)
show more...
Ruhling, M. (author)
Ashton, Nicholas J. (author)
Gothenburg University,Göteborgs universitet,Wallenberg Centre for Molecular and Translational Medicine,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Zetterberg, Henrik, 1973 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Duzel, E. (author)
Hammerer, D. (author)
Betts, M. J. (author)
show less...
 (creator_code:org_t)
2023-03-29
English.
In: Brain Communications. - : Oxford University Press (OUP). - 2632-1297. ; 5:3
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The noradrenergic system shows pathological modifications in aging and neurodegenerative diseases and undergoes substantial neuronal loss in Alzheimer's disease and Parkinson's disease. While a coherent picture of structural decline in post-mortem and in vivo MRI measures seems to emerge, whether this translates into a consistent decline in available noradrenaline levels is unclear. We conducted a meta-analysis of noradrenergic differences in Alzheimer's disease dementia and Parkinson's disease using CSF and PET biomarkers. CSF noradrenaline and 3-methoxy-4-hydroxyphenylglycol levels as well as noradrenaline transporters availability, measured with PET, were summarized from 26 articles using a random-effects model meta-analysis. Compared to controls, individuals with Parkinson's disease showed significantly decreased levels of CSF noradrenaline and 3-methoxy-4-hydroxyphenylglycol, as well as noradrenaline transporters availability in the hypothalamus. In Alzheimer's disease dementia, 3-methoxy-4-hydroxyphenylglycol but not noradrenaline levels were increased compared to controls. Both CSF and PET biomarkers of noradrenergic dysfunction reveal significant alterations in Parkinson's disease and Alzheimer's disease dementia. However, further studies are required to understand how these biomarkers are associated to the clinical symptoms and pathology. Lancini et al. showed that compared to controls, CSF and PET noradrenergic biomarkers are decreased in Parkinson's disease, while in Alzheimer's disease, only CSF noradrenaline metabolite 3-methoxy-4-hydroxyphenylglycol levels are significantly increased. Further studies should determine how CSF measures of noradrenergic dysfunction are related to pathology and clinical symptoms.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

noradrenaline
norepinephrine
Alzheimer's disease
Parkinson's disease
locus coeruleus
locus-coeruleus
parkinsons-disease
alzheimers-disease
senile
dementia
frontal-cortex
neuron loss
norepinephrine
noradrenaline
mechanisms
dopamine
Neurosciences & Neurology

Publication and Content Type

ref (subject category)
art (subject category)

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view